1. Home
  2. Companies
  3. RAD
  4. Material Events

Radiopharm Theranostics (ASX:RAD) — Material Events

ASX:RAD · 21 articles in the last 12 months · 100% assessed

Click a band to jump to that tier

Significant 20 articles Notable 1 article Not Assessed 0 articles
Major ≥90 Significant 75–89 Notable 50–74 Routine <50 Not assessed
Significant Score 75–89
20
Radiopharm’s cash runway tightens as loss widens and clinical pipeline advancesHigh
Radiopharm reports A$56.3m FY2026 loss and material going concern uncertainty as clinical programs advance
30 Sept 2026 ·Annual Report - Form 20-F ·88
Radiopharm’s RAD 101 Hits 92% Concordance in Brain Metastases TrialMedium
Radiopharm Theranostics' RAD 101 achieves 92% concordance with MRI in Phase 2b brain metastases trial
15 Dec 2025 ·Clinical Trial Interim Results ·85
Radiopharm Theranostics Hits 90% Concordance in Brain Metastases Imaging TrialMedium
Radiopharm Theranostics Reports 90% Concordance in Phase 2b Trial of RAD 101 for Brain Metastases
24 Mar 2026 ·Clinical Trial Update ·85
Radiopharm Theranostics Advances Brain Cancer Imaging with 92% MRI ConcordanceMedium
Radiopharm Theranostics reports positive Phase 2b interim data, advances multiple clinical trials, and secures $34.5M cash runway into 2027
28 Jan 2026 ·Quarterly Activities & Cash Report ·85
Radiopharm Theranostics Advances Clinical Pipeline Amid Rising Losses and $35M Capital RaiseMedium
Radiopharm Theranostics reports increased loss, advances multiple clinical trials, and completes $35M capital raise
27 Feb 2026 ·Interim Financial Report ·85
Radiopharm Theranostics Launches First Human Trial of Novel Prostate Cancer TherapyMedium
Radiopharm Theranostics Gets Approval to Start Phase 1 Trial of RAD 402 in Advanced Prostate Cancer
18 Nov 2025 ·Clinical Trial Initiation Announcement ·85
Radiopharm Theranostics and Siemens Healthineers Partner to Supply RAD101 for Phase 3 Brain Metastases TrialMedium
Radiopharm Theranostics and Siemens Healthineers partner to supply RAD101 for Phase 3 brain metastases trial
7 Apr 2026 ·ASX Announcement ·85
Radiopharm Theranostics Advances Clinical Pipeline with $40M Capital BoostHigh
Radiopharm Theranostics advances clinical pipeline, secures A$40M funding, and appoints leading oncologist
28 Oct 2025 ·Quarterly Activities and Cash Flow Report ·85
Radiopharm's 177Lu-RAD202 Shows Promising Safety and Tumor Uptake in Early HER2+ TrialMedium
Radiopharm Theranostics Reports Positive Phase 1 Trial Results for 177Lu-RAD202 in HER2+ Tumors
20 Apr 2026 ·Clinical Trial Update ·85
Radiopharm Theranostics Doses First Patient in Pioneering BetaBart TrialMedium
Radiopharm Theranostics doses first patient in Phase 1/2a trial of BetaBart radiotherapeutic
24 Feb 2026 ·Clinical Trial Update ·85
Radiopharm Advances RAD101 and RAD204 with Strong Trial Results and Phase 3 PlansMedium
Radiopharm Theranostics reports durable partial response and favorable safety in Phase 1 trial of RAD204
22 July 2026 ·Clinical Trial Update ·85
Radiopharm clears FDA meeting hurdle as RAD101 moves towards Phase 3High
Radiopharm advances RAD101 toward Phase 3 after constructive FDA meeting
5 Oct 2026 ·Regulatory and clinical development update ·82
Radiopharm Completes Phase 2b Trial for RAD 101 with 90% MRI ConcordanceMedium
Radiopharm Completes Phase 2b Trial Enrollment for RAD 101 Brain Metastases Imaging; Plans Phase 3
16 Apr 2026 ·Clinical Trial Update ·80
Radiopharm Theranostics Doses First Patient in RAD 402 Trial for Advanced Prostate CancerMedium
Radiopharm Theranostics initiates Phase 1 trial of RAD 402 in advanced prostate cancer
27 Mar 2026 ·Clinical Trial Update ·80
Radiopharm Theranostics Advances 177Lu-RAD204 Trial with Higher Dose ApprovalMedium
Radiopharm Theranostics advances Phase 1 trial of 177Lu-RAD204 with dose escalation to 90mCi
12 Nov 2025 ·Clinical Trial Update ·80
Radiopharm Theranostics Hits 50% Enrollment in RAD101 Brain Metastases TrialMedium
Radiopharm Theranostics Hits 50% Enrollment in Phase 2b RAD101 Brain Metastases Imaging Trial
17 Nov 2025 ·Clinical Trial Update ·80
Radiopharm Theranostics Advances RAD101 Phase 3 Trial Planning with FDA Meeting SetMedium
Radiopharm Theranostics to meet FDA on Phase 3 trial design for RAD101 brain metastases imaging
17 Aug 2026 ·Regulatory Update ·75
Radiopharm Theranostics Advances Multiple Trials Amid $14.9M Quarterly Cash BurnMedium
Radiopharm Theranostics advances clinical trials, reports $19.2M cash with $14.9M quarterly burn
23 Apr 2026 ·Quarterly Activities and Cash Flow Report ·75
Radiopharm Theranostics Advances Phase 1 Trial of 177Lu-RAD202 to Next Dose LevelMedium
Radiopharm Theranostics Advances Phase 1 Trial of 177Lu-RAD202 to Next Dose Level
8 Apr 2026 ·Clinical Trial Update ·75
Radiopharm Theranostics Advances RV-01 Trial with 70 mCi Dose in Solid TumorsMedium
Radiopharm Theranostics doses first patient in second cohort of Phase 1/2a RV-01 trial for B7-H3 solid tumors
26 Aug 2026 ·Clinical Trial Update ·75
Not Assessed Low Score, or missing data
0

No articles in this tier for the last 12 months.